ArticleProceedings of the National Academy of Sciences of the United States of America1999
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.Targeted oncology · 2018Pooled it
- A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.PloS one · 2006Trial
- Transposable Element Activation: A Hallmark of Cancer.Cancer discovery · 2026Review
- Viral mimicry acts as a tumor suppressor in colitis.Nature communications · 2026Article
- Exploring the gut microbiome's role in colorectal cancer: diagnostic and prognostic implications.Frontiers in immunology · 2024Review
- Oncogenic Transformation Drives DNA Methylation Loss and Transcriptional Activation at Transposable Element Loci.Cancer research · 2023Article
- Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics.British journal of cancer · 2023Review
- Inhibiting DNA methylation improves antitumor immunity in ovarian cancer.The Journal of clinical investigation · 2022Article
- Role of Transposable Elements in Genome Stability: Implications for Health and Disease.International journal of molecular sciences · 2022Review
- Transposable element regulation and expression in cancer.The FEBS journal · 2022Review
- Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer.Clinical epigenetics · 2021Article
- Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in aCancer research · 2021Article
- Leveraging epigenetics to enhance the efficacy of immunotherapy.Clinical epigenetics · 2021Review
- Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Advances in epigenetic therapeutics with focus on solid tumors.Clinical epigenetics · 2021Review
- Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.Cellular and molecular life sciences : CMLS · 2021Review
- Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter.Frontiers in oncology · 2021Review
- Combining epigenetic and immune therapy to overcome cancer resistance.Seminars in cancer biology · 2020Review
- Loci specific epigenetic drug sensitivity.Nucleic acids research · 2020Article
- Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model.Cancer immunology, immunotherapy : CII · 2020Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Inhibitors of DNA methyltransferase, typified by 5-aza-2'-deoxycytidine (5-Aza-CdR), induce the expression of genes transcriptionally down-regulated by de novo methylation in tumor cells. We utilized gene expression microarrays to examine the effects of 5-Aza-CdR treatment in HT29 colon adenocarcinoma cells. This analysis revealed the induction of a set of genes that implicated IFN signaling in the HT29 cellular response to 5-Aza-CdR. Subsequent investigations revealed that the induction of this gene set correlates with the induction of signal transducer and activator of transcription (STAT) 1, 2, and 3 genes and their activation by endogenous IFN-alpha. These observations implicate the induction of the IFN-response pathway as a major cellular response to 5-Aza-CdR and suggests that the expression of STATs 1, 2, and 3 can be regulated by DNA methylation. Consistent with STAT's limiting cell responsiveness to IFN, we found that 5-Aza-CdR treatment sensitized HT29 cells to growth inhibition by exogenous IFN-alpha2a, indicating that 5-Aza-CdR should be investigated as a potentiator of IFN responsiveness in certain IFN-resistant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.